Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
management of patients with stage III NSCLC in Central European centres/
countries. The project is a multicentre, prospective, non-interventional
registry. Methods: After ethical committee approval and signed informed
consent, the data about diagnostic and therapeutic procedures of
consecutive patients diagnosed with stage III NSCLC (UICC7) were collected
in web-based registry organised by the IBA MUNI, Brno, Czech Republic.
Results: With cut-off 30 June 2016, 509 patients from 7 countries/16 centres
were enrolled, median number of patients per centre being 23 (range 6-99).
There were 163 (32%) women and 37 (7%) never smokers. Performance status
distribution was as follows: ECOG 0, 1, 2 and 3 in 29%, 56%, 12% and 3%,
respectively. Squamous cancer was found in 52%, adenocarcinoma in 39%,
not otherwise specified in 5% and others in 4% of cases. Genetic mutations
were examined in 119 (23%) patients, predominantly EGFR in 111 subjects
with 10 (8%) positive findings, while the ALK mutation in 64 patients with no
positive finding. Regular staging procedures were X-Ray scan (97%), chest CT
(96%) and bronchoscopy (89%). Staging was completed by abdominal CT in
66% of patients, abdominal US in 29%, PET/CT in 22%, bone scan in 17% and
brain CT or MRI in 13%, respectively. Stage IIIA was found in 59% and stage
IIIB in 41% of patients. N2/N3 nodes were diagnosed in 60%/22% of patients.
Pathological mediastinal lymph-node positivity was confirmed in 109 (21%)
patients (6% EBUS, 0.2% VATS, 1% mediastinoscopy, 1% transbronchial
biopsy and 13% surgery). Median time from diagnosis to first treatment
was 23 days (range 0–321). Treatment procedures were: surgery 138 (27%),
chest radiotherapy 246 (48%) and chemotherapy 409 (80%) of subjects,
respectively. Chemotherapy as only modality was given in 136 (27%) of
patients. Surgery was combined with radiation in 6 cases, with chemotherapy
in 79 (16%) cases and with both chemotherapy and radiotherapy in 37 (7%)
patients. Chemotherapy plus radiotherapy was given in 159 (31%) patients
including concurrent chemoradiotherapy in 67 (13%) cases. At the time of
cut-off, 64% patients were alive, median survival time was not reached,
and the 1-year estimated survival rate was 71%. Conclusion: The most
prevalent histology was squamous cancer. Histopathological examination
of mediastinal lymph-nodes was done in 21% of patients, mostly during
surgery. Majority of patients (55%) were treated with combination therapy.
Palliative chemotherapy only was given in 27% of patients. Survival data are
not mature.
Keywords: treatment modality, non-small cell lung cancer, stage III, diagnostic
procedures
POSTER SESSION 2 – P2.02: LOCALLY ADVANCED NSCLC
CLINICAL OUTCOME –
TUESDAY, DECEMBER 6, 2016
P2.02-012 LONG-TERM SURVIVAL OF PHASE II OF FULL-DOSE ORAL
VINORELBINE COMBINED WITH CISPLATIN & RADIOTHERAPY IN
LOCALLY ADVANCED NSCLC
Óscar Juan 1 , Sergio Vazquez 2 , Joaquin Casal Rubio 3 , Jose Luis Fírvida 4 ,
Francisco Aparisi 5 , José Muñóz 6 , José García Sánchez 7 , Regina Gironés 8 , Martin
Lazaro Quintela 9 , Vicente Giner 10 , Alfredo Sánchez Hernández 11
1 Medical Oncology, Hospital Universitari I Politècnic La Fe, Valencia/Spain,
2 Medical Oncology, Hospital Universitario Lucus Augusti, Lugo/Spain, 3 Medical
Oncology, Complejo Hospitalario Universitario de Vigo, Vigo/Spain, 4 Medical
Oncology, Complexo Hospitalario Universitario de Ourense, Ourense/Spain,
5 Medical Oncology, Hospital Virgen de Los Lirios, Alcoy/Spain, 6 Medical Oncology,
University Hospital Doctor Peset, Valencia/Spain, 7 Medical Oncology, University
Hospital Arnau de Vilanova, Valencia/Spain, 8 Medical Oncology, Hospital Lluis
Alcanyís, Xátiva/Spain, 9 Medical Oncology, Hospitality Complex Xeral-Cies de Vigo,
Vigo/Spain, 10 Medical Oncology, Hospital de Sagunto, Sagunto/Spain, 11 Medical
Oncology, Provincial Hospital de Castellón, Castellón/Spain
Background: Chemo-radiotherapy is the standard of care for the treatment
of inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
Cisplatin (P) plus vinorelbine is one of the chemotherapy (CT) regimens
widely used concurrently with radiotherapy (RT). Since oral vinorelbine (oV)
has achieved comparable results to the IV formulation, the optimal dose for
the oV administration with P and concurrent RT is still being investigated.
The aim of this study is to evaluate the efficacy and safety of full-dose oV
combined with P and radical RT for LA-NSCLC patients (pts). Methods:
Untreated pts between 18-70 years (y), with histologically proven inoperable
LA-NSCLC (supraclavicular lymph node involvement excluded), V20